Radionuclide Therapy for Neuroendocrine Tumors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-02-20

AUTHORS

Mauro Cives, Jonathan Strosberg

ABSTRACT

Peptide receptor radionuclide therapy (PRRT) is a form of systemic radiotherapy that allows targeted delivery of radionuclides to tumor cells expressing high levels of somatostatin receptors. The two radiopeptides most commonly used for PRRT, 90Y-DOTATOC and 177Lu-DOTATATE, have been successfully employed for more than a decade for the treatment of advanced neuroendocrine tumors (NETs). Recently, the phase III, randomized NETTER-1 trial has compared 177Lu-DOTATATE versus high-dose octreotide LAR in patients with progressive, metastatic midgut NETs, demonstrating exceptional tolerability and efficacy. This review summarizes recent developments in the field of radionuclide therapy for gastroenteropancreatic and lung NETs and considers possible strategies to further enhance its clinical efficacy. More... »

PAGES

9

References to SciGraph publications

  • 2013-10-02. Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2015-06-26. Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2011-09-03. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2003-01-09. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2015-11-27. Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2013-11-14. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2011-05-11. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs) in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2010-10-30. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2015-09-21. Long-term results of PRRT in advanced bronchopulmonary carcinoid in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2014-07-29. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2002-10-29. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2014-10-02. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2008-01-16. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2014-10-16. SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors in MOLECULAR IMAGING AND BIOLOGY
  • 2002-05. Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors in VIRCHOWS ARCHIV
  • 2014-03-11. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2010-08-23. Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy in BMC CANCER
  • 2014-05-21. Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT) in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2008-04-22. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2015-03-26. Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2014-02-07. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2015-08-09. The efficacy of 177Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2008-01-11. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2011-05-07. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2002-11-16. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s11912-017-0567-8

    DOI

    http://dx.doi.org/10.1007/s11912-017-0567-8

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1083852167

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/28220446


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Clinical Trials, Phase III as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lung", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neuroendocrine Tumors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Octreotide", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Organometallic Compounds", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pancreas", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Radioisotopes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Radiopharmaceuticals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptors, Somatostatin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Stomach", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, 33612, Tampa, FL, USA", 
              "id": "http://www.grid.ac/institutes/grid.468198.a", 
              "name": [
                "Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, 33612, Tampa, FL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Cives", 
            "givenName": "Mauro", 
            "id": "sg:person.01114625607.45", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114625607.45"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, 33612, Tampa, FL, USA", 
              "id": "http://www.grid.ac/institutes/grid.468198.a", 
              "name": [
                "Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, 33612, Tampa, FL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Strosberg", 
            "givenName": "Jonathan", 
            "id": "sg:person.01114133577.18", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114133577.18"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s00259-014-2735-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014772803", 
              "https://doi.org/10.1007/s00259-014-2735-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-015-3105-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027734738", 
              "https://doi.org/10.1007/s00259-015-3105-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-015-3155-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032781045", 
              "https://doi.org/10.1007/s00259-015-3155-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-013-2559-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018102836", 
              "https://doi.org/10.1007/s00259-013-2559-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-002-0982-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046951944", 
              "https://doi.org/10.1007/s00259-002-0982-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-007-0691-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034879030", 
              "https://doi.org/10.1007/s00259-007-0691-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-002-1050-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045597456", 
              "https://doi.org/10.1007/s00259-002-1050-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-013-2677-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038002606", 
              "https://doi.org/10.1007/s00259-013-2677-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-015-3190-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021523201", 
              "https://doi.org/10.1007/s00259-015-3190-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-015-3041-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051926813", 
              "https://doi.org/10.1007/s00259-015-3041-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-014-2893-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023409614", 
              "https://doi.org/10.1007/s00259-014-2893-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-011-1902-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019962478", 
              "https://doi.org/10.1007/s00259-011-1902-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-008-0778-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043613757", 
              "https://doi.org/10.1007/s00259-008-0778-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-014-2788-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018243354", 
              "https://doi.org/10.1007/s00259-014-2788-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-013-2578-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052062834", 
              "https://doi.org/10.1007/s00259-013-2578-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-007-0688-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016804176", 
              "https://doi.org/10.1007/s00259-007-0688-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1471-2407-10-448", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036359049", 
              "https://doi.org/10.1186/1471-2407-10-448"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-014-2857-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013068868", 
              "https://doi.org/10.1007/s00259-014-2857-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-010-1631-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028002113", 
              "https://doi.org/10.1007/s00259-010-1631-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11307-014-0795-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029679413", 
              "https://doi.org/10.1007/s11307-014-0795-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-011-1833-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010106448", 
              "https://doi.org/10.1007/s00259-011-1833-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-002-1023-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050769026", 
              "https://doi.org/10.1007/s00259-002-1023-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00428-002-0609-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034580135", 
              "https://doi.org/10.1007/s00428-002-0609-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-015-3262-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029523670", 
              "https://doi.org/10.1007/s00259-015-3262-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00259-011-1835-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021370316", 
              "https://doi.org/10.1007/s00259-011-1835-8"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2017-02-20", 
        "datePublishedReg": "2017-02-20", 
        "description": "Peptide receptor radionuclide therapy (PRRT) is a form of systemic radiotherapy that allows targeted delivery of radionuclides to tumor cells expressing high levels of somatostatin receptors. The two radiopeptides most commonly used for PRRT, 90Y-DOTATOC and 177Lu-DOTATATE, have been successfully employed for more than a decade for the treatment of advanced neuroendocrine tumors (NETs). Recently, the phase III, randomized NETTER-1 trial has compared 177Lu-DOTATATE versus high-dose octreotide LAR in patients with progressive, metastatic midgut NETs, demonstrating exceptional tolerability and efficacy. This review summarizes recent developments in the field of radionuclide therapy for gastroenteropancreatic and lung NETs and considers possible strategies to further enhance its clinical efficacy.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s11912-017-0567-8", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1021174", 
            "issn": [
              "1523-3790", 
              "1534-6269"
            ], 
            "name": "Current Oncology Reports", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "2", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "19"
          }
        ], 
        "keywords": [
          "peptide receptor radionuclide therapy", 
          "neuroendocrine tumors", 
          "radionuclide therapy", 
          "high-dose octreotide LAR", 
          "metastatic midgut neuroendocrine tumors", 
          "NETTER-1 trial", 
          "advanced neuroendocrine tumors", 
          "receptor radionuclide therapy", 
          "midgut neuroendocrine tumors", 
          "lung neuroendocrine tumors", 
          "octreotide LAR", 
          "clinical efficacy", 
          "somatostatin receptors", 
          "systemic radiotherapy", 
          "tumor cells", 
          "therapy", 
          "phase III", 
          "delivery of radionuclides", 
          "tumors", 
          "efficacy", 
          "high levels", 
          "tolerability", 
          "patients", 
          "radiotherapy", 
          "radiopeptides", 
          "trials", 
          "receptors", 
          "treatment", 
          "possible strategies", 
          "delivery", 
          "cells", 
          "review", 
          "LAR", 
          "levels", 
          "development", 
          "strategies", 
          "recent developments", 
          "decades", 
          "radionuclides", 
          "form", 
          "field"
        ], 
        "name": "Radionuclide Therapy for Neuroendocrine Tumors", 
        "pagination": "9", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1083852167"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s11912-017-0567-8"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "28220446"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s11912-017-0567-8", 
          "https://app.dimensions.ai/details/publication/pub.1083852167"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-11-24T21:01", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_733.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s11912-017-0567-8"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11912-017-0567-8'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11912-017-0567-8'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11912-017-0567-8'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11912-017-0567-8'


     

    This table displays all metadata directly associated to this object as RDF triples.

    253 TRIPLES      21 PREDICATES      102 URIs      69 LITERALS      18 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s11912-017-0567-8 schema:about N0738031fc0d741489c19475f14e7b689
    2 N4a00ad2a49a14e1aa91e1e3a01c43f58
    3 N65b34f0426714185a90e6d7c3267f99d
    4 N7467074480fb4fe28948bc49cbfb91b2
    5 N77c4d59ed8b6408d9ddefe2e1ced94f1
    6 Na7c512e7e7b54a5a8f8e3ece81e12581
    7 Ncde3cd1549fb40b485fe479605b8b88e
    8 Nd3de42a185e64898b917dcebcd8b0dd5
    9 Nede7c979701840f09945b7ba06e41cde
    10 Nefde74abee504fa98a1c01459783d033
    11 Nf6df54d44ca0401f88dde76775640636
    12 anzsrc-for:11
    13 anzsrc-for:1112
    14 schema:author N3a6505f757f34c2fb9b57dd32c27356c
    15 schema:citation sg:pub.10.1007/s00259-002-0982-3
    16 sg:pub.10.1007/s00259-002-1023-y
    17 sg:pub.10.1007/s00259-002-1050-8
    18 sg:pub.10.1007/s00259-007-0688-7
    19 sg:pub.10.1007/s00259-007-0691-z
    20 sg:pub.10.1007/s00259-008-0778-1
    21 sg:pub.10.1007/s00259-010-1631-x
    22 sg:pub.10.1007/s00259-011-1833-x
    23 sg:pub.10.1007/s00259-011-1835-8
    24 sg:pub.10.1007/s00259-011-1902-1
    25 sg:pub.10.1007/s00259-013-2559-8
    26 sg:pub.10.1007/s00259-013-2578-5
    27 sg:pub.10.1007/s00259-013-2677-3
    28 sg:pub.10.1007/s00259-014-2735-5
    29 sg:pub.10.1007/s00259-014-2788-5
    30 sg:pub.10.1007/s00259-014-2857-9
    31 sg:pub.10.1007/s00259-014-2893-5
    32 sg:pub.10.1007/s00259-015-3041-6
    33 sg:pub.10.1007/s00259-015-3105-7
    34 sg:pub.10.1007/s00259-015-3155-x
    35 sg:pub.10.1007/s00259-015-3190-7
    36 sg:pub.10.1007/s00259-015-3262-8
    37 sg:pub.10.1007/s00428-002-0609-x
    38 sg:pub.10.1007/s11307-014-0795-3
    39 sg:pub.10.1186/1471-2407-10-448
    40 schema:datePublished 2017-02-20
    41 schema:datePublishedReg 2017-02-20
    42 schema:description Peptide receptor radionuclide therapy (PRRT) is a form of systemic radiotherapy that allows targeted delivery of radionuclides to tumor cells expressing high levels of somatostatin receptors. The two radiopeptides most commonly used for PRRT, 90Y-DOTATOC and 177Lu-DOTATATE, have been successfully employed for more than a decade for the treatment of advanced neuroendocrine tumors (NETs). Recently, the phase III, randomized NETTER-1 trial has compared 177Lu-DOTATATE versus high-dose octreotide LAR in patients with progressive, metastatic midgut NETs, demonstrating exceptional tolerability and efficacy. This review summarizes recent developments in the field of radionuclide therapy for gastroenteropancreatic and lung NETs and considers possible strategies to further enhance its clinical efficacy.
    43 schema:genre article
    44 schema:isAccessibleForFree false
    45 schema:isPartOf Na71ddb3e20cb421ab75fa25176386bd5
    46 Nf535e9142aa74e9591b58a6a27e6e020
    47 sg:journal.1021174
    48 schema:keywords LAR
    49 NETTER-1 trial
    50 advanced neuroendocrine tumors
    51 cells
    52 clinical efficacy
    53 decades
    54 delivery
    55 delivery of radionuclides
    56 development
    57 efficacy
    58 field
    59 form
    60 high levels
    61 high-dose octreotide LAR
    62 levels
    63 lung neuroendocrine tumors
    64 metastatic midgut neuroendocrine tumors
    65 midgut neuroendocrine tumors
    66 neuroendocrine tumors
    67 octreotide LAR
    68 patients
    69 peptide receptor radionuclide therapy
    70 phase III
    71 possible strategies
    72 radionuclide therapy
    73 radionuclides
    74 radiopeptides
    75 radiotherapy
    76 recent developments
    77 receptor radionuclide therapy
    78 receptors
    79 review
    80 somatostatin receptors
    81 strategies
    82 systemic radiotherapy
    83 therapy
    84 tolerability
    85 treatment
    86 trials
    87 tumor cells
    88 tumors
    89 schema:name Radionuclide Therapy for Neuroendocrine Tumors
    90 schema:pagination 9
    91 schema:productId N4e2bca64af024a1d85e467000a969d3d
    92 N5c30d3d20f634b63945ba3e554bebf5a
    93 Nc4ef41f0f4fe488082c4e9d5e1955e6c
    94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083852167
    95 https://doi.org/10.1007/s11912-017-0567-8
    96 schema:sdDatePublished 2022-11-24T21:01
    97 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    98 schema:sdPublisher Nd49ecce594be4c66be774be18b84f669
    99 schema:url https://doi.org/10.1007/s11912-017-0567-8
    100 sgo:license sg:explorer/license/
    101 sgo:sdDataset articles
    102 rdf:type schema:ScholarlyArticle
    103 N0738031fc0d741489c19475f14e7b689 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    104 schema:name Neuroendocrine Tumors
    105 rdf:type schema:DefinedTerm
    106 N2a530fb05b2740a7ac9215eca54c301c rdf:first sg:person.01114133577.18
    107 rdf:rest rdf:nil
    108 N3a6505f757f34c2fb9b57dd32c27356c rdf:first sg:person.01114625607.45
    109 rdf:rest N2a530fb05b2740a7ac9215eca54c301c
    110 N4a00ad2a49a14e1aa91e1e3a01c43f58 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    111 schema:name Lung
    112 rdf:type schema:DefinedTerm
    113 N4e2bca64af024a1d85e467000a969d3d schema:name pubmed_id
    114 schema:value 28220446
    115 rdf:type schema:PropertyValue
    116 N5c30d3d20f634b63945ba3e554bebf5a schema:name doi
    117 schema:value 10.1007/s11912-017-0567-8
    118 rdf:type schema:PropertyValue
    119 N65b34f0426714185a90e6d7c3267f99d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    120 schema:name Stomach
    121 rdf:type schema:DefinedTerm
    122 N7467074480fb4fe28948bc49cbfb91b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name Pancreas
    124 rdf:type schema:DefinedTerm
    125 N77c4d59ed8b6408d9ddefe2e1ced94f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name Radioisotopes
    127 rdf:type schema:DefinedTerm
    128 Na71ddb3e20cb421ab75fa25176386bd5 schema:issueNumber 2
    129 rdf:type schema:PublicationIssue
    130 Na7c512e7e7b54a5a8f8e3ece81e12581 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Organometallic Compounds
    132 rdf:type schema:DefinedTerm
    133 Nc4ef41f0f4fe488082c4e9d5e1955e6c schema:name dimensions_id
    134 schema:value pub.1083852167
    135 rdf:type schema:PropertyValue
    136 Ncde3cd1549fb40b485fe479605b8b88e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Clinical Trials, Phase III as Topic
    138 rdf:type schema:DefinedTerm
    139 Nd3de42a185e64898b917dcebcd8b0dd5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    140 schema:name Octreotide
    141 rdf:type schema:DefinedTerm
    142 Nd49ecce594be4c66be774be18b84f669 schema:name Springer Nature - SN SciGraph project
    143 rdf:type schema:Organization
    144 Nede7c979701840f09945b7ba06e41cde schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Humans
    146 rdf:type schema:DefinedTerm
    147 Nefde74abee504fa98a1c01459783d033 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Radiopharmaceuticals
    149 rdf:type schema:DefinedTerm
    150 Nf535e9142aa74e9591b58a6a27e6e020 schema:volumeNumber 19
    151 rdf:type schema:PublicationVolume
    152 Nf6df54d44ca0401f88dde76775640636 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Receptors, Somatostatin
    154 rdf:type schema:DefinedTerm
    155 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    156 schema:name Medical and Health Sciences
    157 rdf:type schema:DefinedTerm
    158 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    159 schema:name Oncology and Carcinogenesis
    160 rdf:type schema:DefinedTerm
    161 sg:journal.1021174 schema:issn 1523-3790
    162 1534-6269
    163 schema:name Current Oncology Reports
    164 schema:publisher Springer Nature
    165 rdf:type schema:Periodical
    166 sg:person.01114133577.18 schema:affiliation grid-institutes:grid.468198.a
    167 schema:familyName Strosberg
    168 schema:givenName Jonathan
    169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114133577.18
    170 rdf:type schema:Person
    171 sg:person.01114625607.45 schema:affiliation grid-institutes:grid.468198.a
    172 schema:familyName Cives
    173 schema:givenName Mauro
    174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114625607.45
    175 rdf:type schema:Person
    176 sg:pub.10.1007/s00259-002-0982-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046951944
    177 https://doi.org/10.1007/s00259-002-0982-3
    178 rdf:type schema:CreativeWork
    179 sg:pub.10.1007/s00259-002-1023-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1050769026
    180 https://doi.org/10.1007/s00259-002-1023-y
    181 rdf:type schema:CreativeWork
    182 sg:pub.10.1007/s00259-002-1050-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045597456
    183 https://doi.org/10.1007/s00259-002-1050-8
    184 rdf:type schema:CreativeWork
    185 sg:pub.10.1007/s00259-007-0688-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016804176
    186 https://doi.org/10.1007/s00259-007-0688-7
    187 rdf:type schema:CreativeWork
    188 sg:pub.10.1007/s00259-007-0691-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1034879030
    189 https://doi.org/10.1007/s00259-007-0691-z
    190 rdf:type schema:CreativeWork
    191 sg:pub.10.1007/s00259-008-0778-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043613757
    192 https://doi.org/10.1007/s00259-008-0778-1
    193 rdf:type schema:CreativeWork
    194 sg:pub.10.1007/s00259-010-1631-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1028002113
    195 https://doi.org/10.1007/s00259-010-1631-x
    196 rdf:type schema:CreativeWork
    197 sg:pub.10.1007/s00259-011-1833-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1010106448
    198 https://doi.org/10.1007/s00259-011-1833-x
    199 rdf:type schema:CreativeWork
    200 sg:pub.10.1007/s00259-011-1835-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021370316
    201 https://doi.org/10.1007/s00259-011-1835-8
    202 rdf:type schema:CreativeWork
    203 sg:pub.10.1007/s00259-011-1902-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019962478
    204 https://doi.org/10.1007/s00259-011-1902-1
    205 rdf:type schema:CreativeWork
    206 sg:pub.10.1007/s00259-013-2559-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018102836
    207 https://doi.org/10.1007/s00259-013-2559-8
    208 rdf:type schema:CreativeWork
    209 sg:pub.10.1007/s00259-013-2578-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052062834
    210 https://doi.org/10.1007/s00259-013-2578-5
    211 rdf:type schema:CreativeWork
    212 sg:pub.10.1007/s00259-013-2677-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038002606
    213 https://doi.org/10.1007/s00259-013-2677-3
    214 rdf:type schema:CreativeWork
    215 sg:pub.10.1007/s00259-014-2735-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014772803
    216 https://doi.org/10.1007/s00259-014-2735-5
    217 rdf:type schema:CreativeWork
    218 sg:pub.10.1007/s00259-014-2788-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018243354
    219 https://doi.org/10.1007/s00259-014-2788-5
    220 rdf:type schema:CreativeWork
    221 sg:pub.10.1007/s00259-014-2857-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013068868
    222 https://doi.org/10.1007/s00259-014-2857-9
    223 rdf:type schema:CreativeWork
    224 sg:pub.10.1007/s00259-014-2893-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023409614
    225 https://doi.org/10.1007/s00259-014-2893-5
    226 rdf:type schema:CreativeWork
    227 sg:pub.10.1007/s00259-015-3041-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051926813
    228 https://doi.org/10.1007/s00259-015-3041-6
    229 rdf:type schema:CreativeWork
    230 sg:pub.10.1007/s00259-015-3105-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027734738
    231 https://doi.org/10.1007/s00259-015-3105-7
    232 rdf:type schema:CreativeWork
    233 sg:pub.10.1007/s00259-015-3155-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1032781045
    234 https://doi.org/10.1007/s00259-015-3155-x
    235 rdf:type schema:CreativeWork
    236 sg:pub.10.1007/s00259-015-3190-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021523201
    237 https://doi.org/10.1007/s00259-015-3190-7
    238 rdf:type schema:CreativeWork
    239 sg:pub.10.1007/s00259-015-3262-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029523670
    240 https://doi.org/10.1007/s00259-015-3262-8
    241 rdf:type schema:CreativeWork
    242 sg:pub.10.1007/s00428-002-0609-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1034580135
    243 https://doi.org/10.1007/s00428-002-0609-x
    244 rdf:type schema:CreativeWork
    245 sg:pub.10.1007/s11307-014-0795-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029679413
    246 https://doi.org/10.1007/s11307-014-0795-3
    247 rdf:type schema:CreativeWork
    248 sg:pub.10.1186/1471-2407-10-448 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036359049
    249 https://doi.org/10.1186/1471-2407-10-448
    250 rdf:type schema:CreativeWork
    251 grid-institutes:grid.468198.a schema:alternateName Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, 33612, Tampa, FL, USA
    252 schema:name Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, 33612, Tampa, FL, USA
    253 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...